- Product Details
Keywords
- Fevipiprant
- high purity
- NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039)
Quick Details
- ProName: Fevipiprant
- CasNo: 872365-14-5
- Molecular Formula: C19H17F3N2O4S
- Appearance: light yellow
- Application: for lab use only
- ProductionCapacity: Metric Ton/Day
- Purity: 98% by HPLC
- LimitNum: 1 Milligram
Superiority
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonistof the prostaglandin D2 receptor 2 (DP2 or CRTh2)
As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]
Novartis is developing fevipiprant, a prostaglandin D2 receptor (PD2/CRTh2) antagonist, as an oral capsule formulation for treating asthma and moderate to severe atopic dermatitis.